Granules India Q3 Net Profit Jumps 28% on Robust Revenue, Wider Margins

• Granules India reported a 27.7% surge in net profit to ₹150.2 crore in Q3FY26, up from ₹117.6 crore year-on-year.
• Revenue for the quarter increased by 22% to ₹1,387.9 crore, driven by strong demand across its diverse pharmaceutical portfolio.
• EBITDA rose 33.4% to ₹308.4 crore, with margins expanding to 22.2% from 20.3% in the previous year.
• Finished dosages (FD) contributed 76% of the revenue, while API and PFI each accounted for 11%, and peptides/CDMO added 2%.
• Chairman & MD Dr. Krishna Prasad Chigurupati highlighted disciplined execution of strategic growth initiatives and ongoing R&D investments as key drivers.

Why It Matters: Granules India achieved significant profit and revenue growth in Q3FY26, driven by strong demand and strategic execution.